Try Alerts Free   |   Login
Health Care › Pharmaceutical Preparations

BHVN Price Correlated With Financials For Biohaven Pharmaceutical Holding Co

Free historical financial statements for Biohaven Pharmaceutical Holding Co. See how revenue, income, cash flow, and balance sheet financials have changed over 9 quarters since 2020. Compare with BHVN stock chart to see long term trends.

BHVN Stock Compared to Quarterly

BHVN Income Statement

Revenue, Net:318852000
Revenue Per Share:4.4881
Cost of Goods & Services Sold:26342000
Selling, General & Admin Expense:227243000
Research & Development Expense:119099000
Total Operating Expenses:372684000
Operating Income:-92594000
Income Taxes:24303000
Net Income:-209072000
Earnings Per Share, Basic:-2.97
Shares Outstanding, Basic Avg:71043181

BHVN Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:4402000
Change in Accounts Receiveable:20073000
Net Cash from Operations:-23644000
Net Cash from Operations Per Share:-0.3328
Net Cash from Financing Activities:267991000
Property, Plant & Equipment Purchases:512000
Net Cash from Investing Activities:-244270000
Net Change in Cash & Equivalents:31000

BHVN Balance Sheet

Cash and Cash Equivalents:174374000
Short-Term Investments:433410000
Accounts Receivable, Net:328342000
Inventories:91281000
Total Current Assets:1171085000
Property, Plant & Equipment, Net:14534000
Total Assets:1371717000
Accounts Payable:56202000
Current Portion of Long-Term Debt:null
Total Short-Term Liabilities:576114000
Long Term Debt, Non-Current Portion:null
Total Liabilities:1838130000
COMPANY PROFILE
Nature of the Business and Basis of Presentation Biohaven Pharmaceutical Holding Company Ltd. (“we,” “us”, "our," "Biohaven" or the “Company”) was incorporated in Tortola, British Virgin Islands in September 2013. We are a biopharmaceutical company with a portfolio of innovative product candidates targeting neurological diseases, including rare disorders. The Company's lead product, NURTEC™ ODT (rimegepant), was approved by the U.S. Food and Drug Administration ("FDA") on February 27, 2020, which became available by prescription in U.S. pharmacies on March 12, 2020, and was approved for the preventive treatment of migraine on May 27, 2021. NURTEC ODT is the first and only calcitonin gene-related peptide ("CGRP") receptor antagonist available in a quick-dissolve orally dissolving tablet ("ODT") formulation that is approved by the FDA for both the acute and preventive treatment of migraine in adults. Our other late-stage product candidates are based on multiple mechanisms — CGRP receptor antagonists, glutamate modulators and myeloperoxidase inhibition—which we believe have the potential to significantly alter existing treatment approaches across a diverse set of neurological indications with high unmet need in both large and orphan indications.

The Company is subject to risks and uncertainties common to companies in the biopharmaceutical industry, including, but not limited to, the risks associated with developing product candidates at each stage of non-clinical and clinical development; the challenges associated with gaining regulatory approval of such product candidates; the risks associated with commercializing pharmaceutical products for marketing and sale; the potential for development by third parties of new technological innovations that may compete with the Company’s products; the dependence on key personnel; the challenges of protecting proprietary technology; the need to comply with government regulations; the high costs of drug development; and the uncertainty of being able to secure additional capital when needed to fund operations.

Subsequent to its May 2017 initial public offering, the Company has primarily raised funds through sales of equity in private placements and public offerings, sales of revenue participation rights related to potential future royalties, and a debt financing. On November 9, 2021, the Company and certain of its affiliates (collectively, the “Company”) entered into a licensing and collaboration arrangement (the “Collaboration Agreement”) with a subsidiary of Pfizer Inc. (“Pfizer”) pursuant to which Pfizer would commercialize product candidates containing the Company’s proprietary compounds rimegepant (BHV-3000) and gain rights to zavegepant

(BHV-3500) (the “Licensed Products”) in all countries worldwide outside of the United States (the “Territory”). The Collaboration Agreement became effective on January 4, 2022. Refer to Note 19, "Subsequent Events," for further details.

The Company has incurred recurring losses since its inception, had an accumulated deficit as of December 31, 2021, and expects to continue to generate operating losses during the continued commercial launch of rimegepant. To execute its business plans, the Company will continue to require additional funding to support its continuing operations and pursue its growth strategy.

Through the date of the issuance of this Form 10-K, the Company has funded its operations primarily with proceeds from sales of preferred and common shares, issuance of debt and and proceeds from our Subscription Agreement and Collaboration Agreement with Pfizer (see Note 19). The Company has incurred recurring losses since its inception, including net losses attributable to the Company of $846,586, $766,796, and $528,805 during the years ended December 31, 2021, 2020 and 2019, respectively, and had an accumulated deficit of $2,585,755 as of December 31, 2021. As a result of the Company’s commercial launch of NURTEC ODT, the continued developmen

Data imported from Biohaven Pharmaceutical Holding Co SEC filings. Check original filings before making any investment decision.